Lexicon Pharmaceuticals, Inc.
LXRX
$1.88
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 123.12% | 60.24% | 1,255.21% | 1,504.83% | 1,250.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 123.12% | 60.24% | 1,255.21% | 1,504.83% | 1,250.63% |
| Cost of Revenue | -16.94% | 20.46% | -127.85% | -118.03% | -113.98% |
| Gross Profit | 100.23% | 41.33% | 267.73% | 249.33% | 167.40% |
| SG&A Expenses | -71.51% | -73.92% | -57.17% | -31.07% | -2.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.78% | -56.53% | -36.42% | -11.82% | 11.11% |
| Operating Income | 86.26% | 75.05% | 68.63% | 40.05% | 4.41% |
| Income Before Tax | 85.28% | 74.88% | 68.31% | 40.32% | 8.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 85.28% | 74.88% | 68.31% | 40.32% | 8.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 85.28% | 74.88% | 68.31% | 40.32% | 8.41% |
| EBIT | 86.26% | 75.05% | 68.63% | 40.05% | 4.41% |
| EBITDA | 86.53% | 75.30% | 68.85% | 40.18% | 4.41% |
| EPS Basic | 86.12% | 78.39% | 74.80% | 57.15% | 37.70% |
| Normalized Basic EPS | 86.02% | 78.26% | 74.98% | 57.20% | 37.62% |
| EPS Diluted | 86.12% | 78.39% | 74.80% | 57.15% | 37.70% |
| Normalized Diluted EPS | 86.02% | 78.26% | 74.98% | 57.20% | 37.62% |
| Average Basic Shares Outstanding | 6.77% | 13.52% | 24.74% | 38.46% | 48.50% |
| Average Diluted Shares Outstanding | 6.79% | 13.54% | 24.76% | 38.48% | 48.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |